• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?对于非典型溶血性尿毒症综合征患者，是否应停用依库珠单抗？
Clin Kidney J. 2017 Jun;10(3):320-322. doi: 10.1093/ckj/sfx024. Epub 2017 Apr 20.
2
A Multicenter Study Evaluating the Discontinuation of Eculizumab Therapy in Children with Atypical Hemolytic Uremic Syndrome.一项评估依库珠单抗治疗非典型溶血性尿毒症综合征儿童停药情况的多中心研究。
Children (Basel). 2022 Nov 11;9(11):1734. doi: 10.3390/children9111734.
3
Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome.一项针对非典型溶血性尿毒症综合征中补体抑制治疗停药的临床医生指导方案的结果。
Blood Adv. 2021 Mar 9;5(5):1504-1512. doi: 10.1182/bloodadvances.2020003175.
4
Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.终端补体抑制剂依库珠单抗治疗成人非典型溶血尿毒综合征：一项单臂、开放标签试验。
Am J Kidney Dis. 2016 Jul;68(1):84-93. doi: 10.1053/j.ajkd.2015.12.034. Epub 2016 Mar 21.
5
Disease Recurrence After Early Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome With Complement C3 I1157T Mutation.一例伴有补体C3 I1157T突变的非典型溶血性尿毒症综合征患者早期停用依库珠单抗后的疾病复发
J Pediatr Hematol Oncol. 2016 Apr;38(3):e137-9. doi: 10.1097/MPH.0000000000000505.
6
Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases.停止依库珠单抗维持治疗非典型溶血尿毒综合征：10 例报告。
Am J Kidney Dis. 2014 Oct;64(4):633-7. doi: 10.1053/j.ajkd.2014.01.434. Epub 2014 Mar 19.
7
Relapse of Atypical Hemolytic Uremic Syndrome During Pregnancy in a Patient on Eculizumab Maintenance Treatment: A Case Report.接受依库珠单抗维持治疗的患者孕期非典型溶血性尿毒症综合征复发：一例报告
Am J Case Rep. 2019 Oct 4;20:1460-1465. doi: 10.12659/AJCR.916994.
8
Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.非典型溶血性尿毒症综合征：病例报告的荟萃分析证实基因突变的患病率及治疗方案的转变
Ther Apher Dial. 2018 Apr;22(2):178-188. doi: 10.1111/1744-9987.12641. Epub 2017 Dec 17.
9
Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.在影响原肾的成人非典型溶血性尿毒症综合征患者的临床实践中使用依库珠单抗的见解：19 例分析。
Am J Kidney Dis. 2014 Jan;63(1):40-8. doi: 10.1053/j.ajkd.2013.07.011. Epub 2013 Sep 8.
10
Successful Treatment of Anti-Factor H Antibody-Associated Atypical Hemolytic Uremic Syndrome.抗凝血因子H抗体相关非典型溶血尿毒综合征的成功治疗
Indian J Nephrol. 2020 Jan-Feb;30(1):35-38. doi: 10.4103/ijn.IJN_336_18. Epub 2019 Sep 6.

引用本文的文献

1
Recommendations for diagnosis and treatment of Atypical Hemolytic Uremic Syndrome (aHUS): an expert consensus statement from the Rare Diseases Committee of the Brazilian Society of Nephrology (COMDORA-SBN).非典型溶血性尿毒症综合征（aHUS）的诊断与治疗建议：巴西肾脏病学会罕见病委员会（COMDORA - SBN）的专家共识声明
J Bras Nefrol. 2025 Apr-Jun;47(2):e20240087. doi: 10.1590/2175-8239-JBN-2024-0087en.
2
A Multicenter Study Evaluating the Discontinuation of Eculizumab Therapy in Children with Atypical Hemolytic Uremic Syndrome.一项评估依库珠单抗治疗非典型溶血性尿毒症综合征儿童停药情况的多中心研究。
Children (Basel). 2022 Nov 11;9(11):1734. doi: 10.3390/children9111734.
3
Different approaches to long-term treatment of aHUS due to MCP mutations: a multicenter analysis.由于 MCP 突变导致的 aHUS 的长期治疗的不同方法：一项多中心分析。
Pediatr Nephrol. 2021 Feb;36(2):463-471. doi: 10.1007/s00467-020-04714-0. Epub 2020 Jul 26.
4
Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: a case report and a review of literature.氟尿嘧啶和奥沙利铂治疗转移性结直肠癌患者的非典型溶血性尿毒症综合征：一例报告并文献复习
ESMO Open. 2019 Sep 19;4(5):e000551. doi: 10.1136/esmoopen-2019-000551. eCollection 2019.
5
Deterioration in Clinical Status Is Not Enough to Suspend Eculizumab: A Genetic Complement-Mediated Atypical Hemolytic Uremic Syndrome Case Report.临床状态恶化不足以停用依库珠单抗：一例遗传性补体介导的非典型溶血尿毒综合征病例报告
Case Rep Nephrol. 2019 Jul 9;2019:9264824. doi: 10.1155/2019/9264824. eCollection 2019.
6
Recent advances in understanding and management of acquired thrombocytopenia.获得性血小板减少症的认识与管理的最新进展
F1000Res. 2018 Jan 17;7:68. doi: 10.12688/f1000research.12309.1. eCollection 2018.

本文引用的文献

1
Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome.关于非典型溶血性尿毒症综合征患者停用依库珠单抗的现有证据。
Clin Kidney J. 2017 Jun;10(3):310-319. doi: 10.1093/ckj/sfw115. Epub 2016 Dec 22.
2
Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.补体基因中的致病性变异与依库珠单抗停药后非典型溶血尿毒症综合征复发的风险。
Clin J Am Soc Nephrol. 2017 Jan 6;12(1):50-59. doi: 10.2215/CJN.06440616. Epub 2016 Oct 31.
3
Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.终端补体抑制剂依库珠单抗治疗成人非典型溶血尿毒综合征：一项单臂、开放标签试验。
Am J Kidney Dis. 2016 Jul;68(1):84-93. doi: 10.1053/j.ajkd.2015.12.034. Epub 2016 Mar 21.
4
Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.依库珠单抗对非典型溶血性尿毒症综合征患儿是一种安全有效的治疗方法。
Kidney Int. 2016 Mar;89(3):701-11. doi: 10.1016/j.kint.2015.11.026. Epub 2016 Jan 28.
5
The global aHUS registry: methodology and initial patient characteristics.全球非典型溶血尿毒综合征注册研究：方法与初始患者特征
BMC Nephrol. 2015 Dec 10;16:207. doi: 10.1186/s12882-015-0195-1.
6
An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.非典型溶血性尿毒症综合征的最新进展：诊断与治疗。一份共识文件。
Nefrologia. 2015;35(5):421-47. doi: 10.1016/j.nefro.2015.07.005. Epub 2015 Oct 9.
7
Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update.非典型溶血性尿毒症综合征中依库珠单抗治疗的停药：最新进展
Am J Kidney Dis. 2015 Jul;66(1):172-3. doi: 10.1053/j.ajkd.2015.04.010.
8
Eculizumab in atypical haemolytic-uraemic syndrome allows cessation of plasma exchange and dialysis.依库珠单抗治疗非典型溶血尿毒综合征可停止血浆置换和透析。
Clin Kidney J. 2012 Feb;5(1):34-6. doi: 10.1093/ndtplus/sfr174. Epub 2012 Jan 30.
9
Early treatment with eculizumab in atypical haemolytic uraemic syndrome.依库珠单抗治疗非典型溶血尿毒综合征。
Clin Kidney J. 2012 Feb;5(1):31-3. doi: 10.1093/ndtplus/sfr157. Epub 2012 Jan 31.
10
Treatment of atypical uraemic syndrome in the era of eculizumab.依库珠单抗时代非典型尿毒症综合征的治疗
Clin Kidney J. 2012 Feb;5(1):4-6. doi: 10.1093/ckj/sfr177.

对于非典型溶血性尿毒症综合征患者，是否应停用依库珠单抗？

Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?

作者信息

Rodriguez Eva, Barrios Clara, Soler Maria José

机构信息

Department of Nephrology, Hospital del Mar, Barcelona, Spain.

Institut Mar for Medical Research, Barcelona, Spain.

出版信息

Clin Kidney J. 2017 Jun;10(3):320-322. doi: 10.1093/ckj/sfx024. Epub 2017 Apr 20.

DOI:10.1093/ckj/sfx024
PMID:28616209
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5466109/
Abstract

Atypical hemolytic uremic syndrome (aHUS) is a life-threatening disorder for which prompt diagnosis and eculizumab treatment is indicated. The time for relapse and patients at risk for relapse after eculizumab discontinuation are unknown. While some authors believe there is no clinical evidence supporting eculizumab discontinuation, which may be associated with high collateral risks such as loss of renal function, other authors believe that the drug can be safely discontinued with close patient monitoring. In this editorial, we update the pros and cons for eculizumab discontinuation in aHUS.

摘要

非典型溶血性尿毒症综合征（aHUS）是一种危及生命的疾病，对此需进行及时诊断并使用依库珠单抗进行治疗。复发时间以及依库珠单抗停药后有复发风险的患者情况尚不清楚。一些作者认为没有临床证据支持停用依库珠单抗，因为这可能会带来如肾功能丧失等高附带风险，而其他作者则认为在对患者进行密切监测的情况下可以安全地停用该药物。在这篇社论中，我们阐述了在aHUS中停用依库珠单抗的利弊。